These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39264638)

  • 1. Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer: A Review.
    Tarantino P; Hortobagyi G; Tolaney SM; Mittendorf EA
    JAMA Oncol; 2024 Nov; 10(11):1578-1584. PubMed ID: 39264638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
    Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
    Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
    Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
    Future Oncol; 2024; 20(31):2343-2355. PubMed ID: 38922307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
    O'Sullivan CC; Ballman KV; McCall L; Kommalapati A; Zemla T; Weiss A; Mitchell M; Blinder V; Tung NM; Irvin WJ; Lee M; Goetz MP; Symmans WF; Borges VF; Krop I; Carey LA; Partridge AH
    Future Oncol; 2021 Dec; 17(34):4665-4676. PubMed ID: 34636255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
    Bossuyt V; Spring L
    Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer.
    Kunst N; Wang SY; Hood A; Mougalian SS; DiGiovanna MP; Adelson K; Pusztai L
    JAMA Netw Open; 2020 Nov; 3(11):e2027074. PubMed ID: 33226431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
    Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy.
    Foldi J; Rozenblit M; Park TS; Knowlton CA; Golshan M; Moran M; Pusztai L
    Curr Treat Options Oncol; 2021 Jul; 22(9):79. PubMed ID: 34213636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
    Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
    Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Conte P; Schneeweiss A; Loibl S; Mamounas EP; von Minckwitz G; Mano MS; Untch M; Huang CS; Wolmark N; Rastogi P; D'Hondt V; Redondo A; Stamatovic L; Bonnefoi H; Castro-Salguero H; Fischer HH; Wahl T; Song C; Boulet T; Trask P; Geyer CE
    Cancer; 2020 Jul; 126(13):3132-3139. PubMed ID: 32286687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
    Ahn HK; Sim SH; Suh KJ; Kim MH; Jeong JH; Kim JY; Lee DW; Ahn JH; Chae H; Lee KH; Kim JH; Lee KS; Sohn JH; Choi YL; Im SA; Jung KH; Park YH
    JAMA Oncol; 2022 Sep; 8(9):1271-1277. PubMed ID: 35797012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
    Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
    LeVasseur N; Sun J; Gondara L; Diocee R; Speers C; Lohrisch C; Chia S
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):529-536. PubMed ID: 31741041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
    Dülgar Ö; Öven BB; Atcı MM; Arıkan R; Ay S; Ayhan M; Selvi O; Ozyukseler DT; Bayram E; Özcan E; Yasin Aİ; Gümüş M
    Expert Rev Anticancer Ther; 2022 Jul; 22(7):773-780. PubMed ID: 35543015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
    Villacampa G; Navarro V; Matikas A; Ribeiro JM; Schettini F; Tolosa P; Martínez-Sáez O; Sánchez-Bayona R; Ferrero-Cafiero JM; Salvador F; Papakonstantinou A; Prat A; Oliveira M; Pascual T
    JAMA Oncol; 2024 Oct; 10(10):1331-1341. PubMed ID: 39207778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.